TriSalus Life Sciences, Inc.
TLSI
$4.76
$0.030.63%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 25.25% | 39.64% | 53.41% | 49.52% | 45.50% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 25.25% | 39.64% | 53.41% | 49.52% | 45.50% |
| Cost of Revenue | 16.11% | 44.80% | 69.75% | 85.04% | 80.65% |
| Gross Profit | 26.90% | 38.78% | 50.77% | 44.26% | 40.55% |
| SG&A Expenses | 15.76% | 15.98% | 15.73% | 14.69% | 12.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.87% | 13.99% | 9.91% | 2.45% | -8.44% |
| Operating Income | 1.52% | 11.92% | 25.49% | 27.08% | 36.00% |
| Income Before Tax | 9.54% | -0.37% | -30.56% | 28.78% | 42.90% |
| Income Tax Expenses | 750.00% | -25.00% | 16.67% | -25.00% | -118.18% |
| Earnings from Continuing Operations | 9.49% | -0.36% | -30.56% | 28.78% | 42.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.49% | -0.36% | -30.56% | 28.78% | 42.91% |
| EBIT | 1.52% | 11.92% | 25.49% | 27.08% | 36.00% |
| EBITDA | 1.05% | 11.72% | 25.69% | 27.43% | 36.53% |
| EPS Basic | -9.90% | -26.05% | -37.37% | 19.50% | 53.37% |
| Normalized Basic EPS | 41.26% | 50.57% | 38.98% | 48.79% | 68.43% |
| EPS Diluted | -9.98% | -25.89% | -37.48% | 19.45% | 53.31% |
| Normalized Diluted EPS | 41.26% | 50.57% | 38.98% | 48.79% | 68.43% |
| Average Basic Shares Outstanding | 73.64% | 64.45% | 49.42% | 36.17% | 38.08% |
| Average Diluted Shares Outstanding | 73.64% | 64.45% | 49.42% | 36.17% | 38.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |